Glenmark Pharmaceuticals receives ANDA approval for Solifenacin Succinate Tablets, 5 mg and 10 mg
Newsroom
Glenmark Pharmaceuticals receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg
14 May 2019 | Read More
Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years
9 May 2019 | Read More
Glenmark appoints Dr. Yasir Rawjee as Chief Executive Officer of Glenmark Life Sciences, its subsidiary for the API business
7 May 2019 | Read More
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
3 May 2019 | Read More
Glenmark launches novel, globally-researched anti-diabetes drug Remogliflozin in India
30 Apr 2019 | Read More
Glenmark receives approval from Russian Ministry of Healthcare to market Momate Rhino metered nasal spray as an Over-the-Counter (OTC) product
25 Apr 2019 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%
15 Mar 2019 | Read More
Glenmark Announces Appointment of Alessandro Riva as CEO of its New Innovation Company
6 Mar 2019 | Read More
Glenmark receives ANDA approval for Telmisartan and Hydrochlorothiazide Tablets USP
5 Mar 2019 | Read More
Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting
4 Mar 2019 | Read More
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at AAAAI 2019 Annual Meeting
26 Feb 2019 | Read More
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
20 Feb 2019 | Read More
Glenmark receives ANDA approval for Clobetasol Propionate Foam, 0.05%
18 Feb 2019 | Read More
Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
14 Feb 2019 | Read More
Glenmark to spin off its innovation business into a new company in the US
14 Feb 2019 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg
11 Feb 2019 | Read More
Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)
7 Feb 2019 | Read More
Glenmark Pharmaceuticals enters into an Exclusive License Agreement with Grandpharma (China) Co. Ltd. for commercializing Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris in China
6 Feb 2019 | Read More
Glenmark receives tentative ANDA approval for Topiramate Extended-Release Capsules
24 Jan 2019 | Read More
Glenmark receives tentative ANDA approval for Abiraterone Acetate Tablets USP, 250 mg
23 Jan 2019 | Read More
Glenmark Pharmaceuticals enters into an Exclusive Licensing Agreement with Yuhan Corporation for commercializing Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris in South Korea
10 Jan 2019 | Read More
Library
Profile – Chairman and Managing Director
With the idea of creating something unique, Glenn Saldanha took over the reins of the company and helped transform it into a global enterprise worth USD 1.4 billion with offices across 40 countries. Download Profile
Profile – Glenmark Pharmaceuticals
Research-driven, global and integrated pharmaceutical company which is driven to meet unmet medical needs and help pave a new way for a new world. Download Profile
For any media related queries, please email corpcomm@glenmarkpharma.com